Scholarlink

<p>This case highlights a young CML patient who achieved a major molecular response (MMR) after just four months with a subtherapeutic dose of asciminib. The patient could not tolerate full-dose asciminib, or the full dose of two previous tyrosine kinase inhibitors (TKI) due to myelotoxicity, but blood counts recovered rapidly upon TKI suspension and reduced dosing enabled sustained treatment. This is the second reported case of the use of 20&#xa0;mg QD asciminib, four times below the recommended dose, and the first to demonstrate efficacy at this dose. The study emphasizes asciminib’s potential for overcoming treatment challenges associated with multi-resistant/intolerant CML patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月7日

查看全文
  • Ruth Stuckey,
  • Laura Navarrete Bullón,
  • Asunción Borrero Borrego,
  • Violeta Vidal Ballester,
  • Carlos Rodríguez-Medina,
  • Alejandro Morales Curbelo,
  • Leslie González Pinedo,
  • Melissa Torres Ochando,
  • Alvaro Veiga Vaz,
  • María del Mar Perera,
  • Cristina Bilbao-Sieyro,
  • Juan Francisco López Rodríguez,
  • Adrián Segura-Díaz,
  • María Teresa Gómez-Casares

摘要

This case highlights a young CML patient who achieved a major molecular response (MMR) after just four months with a subtherapeutic dose of asciminib. The patient could not tolerate full-dose asciminib, or the full dose of two previous tyrosine kinase inhibitors (TKI) due to myelotoxicity, but blood counts recovered rapidly upon TKI suspension and reduced dosing enabled sustained treatment. This is the second reported case of the use of 20 mg QD asciminib, four times below the recommended dose, and the first to demonstrate efficacy at this dose. The study emphasizes asciminib’s potential for overcoming treatment challenges associated with multi-resistant/intolerant CML patients.